

Information on candidates nominated for election or re-election to the board

Re election

Bo Jesper Hansen

Chairman and Board member since 2013. Born 1958. MD. PhD. Other appointments: Chairman of Swedish Orphan Biovitrum AB and Topotarget A/S. Board member of Hyperion Therapeutics Inc., GenSpera Inc., Newron SA, Ablynx NV, Orphazyme A/S and CMC Kontrast AB. Previous appointments include various positions in Swedish Orphan International AB since 1993, including CEO 1998–2010. Medical advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi. Founder of Scandinavian Medical Research.

Independent of the company and its senior management, as well as of major shareholders in the company.

Hans Wigzell

Director since 2006. Born 1938. Professor of Immunology and MD. Other appointments: Chairman of Rhenman & Partner Asset Management AB. Board member of AVI Biopharma Inc., Swedish Orphan Biovitrum AB, Humalabs LLC, Intercell AG and RaySearch Laboratories AB. Member of The Royal Swedish Academy of Engineering Sciences and of the Royal Swedish Academy of Sciences. Previous assignments include, among others, the President of Karolinska Institutet's Nobel Committee, and President of Karolinska Institutet and Director General of Smittskyddsinstitutet. Holdings in Karolinska Development 8,491 shares.

Independent of the company and its senior management, as well as of major shareholders in the company.

Holdings in Karolinska Development 8 491 shares, series B.

Vlad Artamonov

Director since 2012. Born 1978. MBA, B.Sc. Other appointments: Board Member of Redbank Energy Ltd. and of Coastal Capital International Ltd., Managing Partner at Coastal Capital International Ltd. Previous appointments include Investment Analyst at Greenlight Capital Inc., position in the Global Merger & Acquisition Group at Merrill Lynch in New York.

Independent of the company and its senior management, as well as of major shareholders in the company.

Holdings in Karolinska Development 3,470,541 shares, series B (by related legal person).

Henriette Richter

Director since 2014. Born 1971. PhD MSc. Other appointments: Investment Director at Novo Seeds, Novo A/S. Chairman of Avilex Pharma ApS and Affinicon ApS, Board member at Orphazyme A/S and EpiTherapeutics A/S, and the Green Development and Demonstration Programme (GUDP) of the Danish Food, Agriculture and Fisheries Ministry. Previous assignments include Chairman of Cytoguide

ApS, Board member at MycoTeq ApS and Nanofence ApS. Member of the Advisory Board at the Institute for Systems Biology, Technical University of Denmark.

Independent of the company and its senior management, as well as of major shareholders in the company.

No holdings in Karolinska Development.

Carl Johan Sundberg

Director since 2014. Born 1958. Professor of Physiology. Other appointments: Board Director of Cobra Biologics AB, Coordinator Science and Society, the Vice-Chancellor's Office at KI, director of the Unit of Bioentrepreneurship, Fellow of the Royal Swedish Academy of Engineering Sciences, member of the Medical Commission of the International Olympic Committee, Inspector General of the Medical Association and Chairman of Research!Sweden. Previous assignments include Investment Director at Karolinska Investment Fund, Board Director of Global Genomics AB, AngioGenetics AB, NsGene AS, Cellectric AB, Alfta Rehab Center Holding AB, Karolinska Education AB and Feelgood Swedish AB, Vice President of Euroscience and Chairman of the Swedish Professional Associations for Physical Activity and Sports Medicine.

Independent of the company and its senior management. Not independent of major shareholders in the company.

No holdings in Karolinska Development.

New election

Tse Ping

Born 1952. Education: Honorary Doctorate, Fil Dr hc. Other appointments: Founder and Chairman of Sino Biopharmaceutical Limited, one of the largest and most successful pharmaceutical companies in Hong Kong. Mr. Tse Ping is also Vice Chairman of Charoen Pokphand Group (CP Group), the largest company in Thailand, where he has extensive experience of major merger and acquisition activity including Ping An Insurance, CITIC Group, China Mobile, ITOCHU Corporation, and Marko Group. Previous appointments: Member of the Ninth, Tenth, and Eleventh National Committee of the Chinese People's Political Consultative Conference.

Independent of the Company and its senior management, as well as major shareholders in the Company.

Holdings in the Company: 4,853,141 shares and SEK 272,858,294 in convertible bonds.

Niclas Adler

Born 1971. Education PhD, MSc. Other appointments: Managing Partner Accelerated Innovation Ltd, President Indonesian International Institute for Life-sciences, Chairman PT Accelerated Value, Chairman e-Cognition PTE Ltd, Chairman ITH Immune Therapy Holdings AB, Chairman TLA Targeted Immunotherapies AB, Chairman Accelerated Drug Development AB and Babson Global Professor of

Entrepreneurship Practice. Previous appointments: President IPMI International Business School, Jakarta, Director Truepoint Partners, Boston, Fellow, Sunningdale Institute, London, Fellow, Centre For International Business and Management, Judge Business School, Cambridge University, CEO Jönköping International Business School, Director FENIX Center for Innovations in Management, Stockholm School of Economics, Executive Director, Stockholm School of Entrepreneurship.

Independent of the Company and its senior management, as well as major shareholders in the Company.

No holdings in the Company.

Khalid Islam

Born 1955. PhD. Other appointments: Board member of Pcovery Aps, Adenium Aps, Oxthera AB, Fennec Pharma Inc. and Molmed SpA.; Advisor to Kurma Biofund, member of the Editorial Board of Current Drug Discovery & Technologies and of the International Scientific Advisory Board of The Network of Excellence for Pathogenomics. Previous appointments: President of Gentium SpA and Arpida AG and various leadership positions in research and development in Hoechst Marion Roussel (HMR) and Marion Merrell Dow (MMD).

Independent of the Company and its senior management, as well as major shareholders in the Company.

No holdings in the Company.